Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1651791 | 1.00 | F10 (0.49) | F10F2SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL1385114 | 0.89 | F10 (0.49) | F10F2PRMT5WDR77LOXL2 | |
| SCHEMBL28748329 | 0.85 | F10 (0.42) | F10F2SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL1653330 | 0.82 | F10 (0.56) | F10F2PRMT5WDR77 | |
| SCHEMBL4399676 | 0.82 | F10 (0.51) | F10F2SMN1; SMN2 | |
| SCHEMBL1386332 | 0.82 | F10 (0.54) | F10F2PRMT5WDR77 | |
| SCHEMBL1652787 | 0.82 | F10 (0.51) | F10F2SMN1; SMN2 | |
| SCHEMBL1653097 | 0.81 | F10 (0.53) | F10F2SMN1; SMN2 | |
| SCHEMBL1654897 | 0.81 | F10 (0.53) | F10F2SMN1; SMN2 | |
| SCHEMBL1652261 | 0.80 | F10 (0.58) | F10F2PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | claimed |
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | F10 12/4885F2 7/4885SMN1; SMN2 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.